SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

FuelCell Energy, Inc. is an American clean energy technology company that delivers continuous, scalable baseload power for mission-critical applications globally. It engages in the development, design, production, construction, operation, and servicing of high-temperature fuel cells for clean electric power generation. The company’s fuel cell systems generate electricity directly at the point of use, enabling reliable, low-emission power for data centers, industrial facilities, utilities, and distributed generation customers. FuelCell Energy delivers commercially proven, modular, utility-scale systems backed by global fuel cell deployments approaching one gigawatt. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

Anticipation of FuelCell Energys Q3 earnings call on September 2 is driving attention, with traders watching for updates on data-center contracts, manufacturing expansion, and the ExxonMobil-linked Rotterdam/PORTHOS carbon-capture demonstration. Bullish traders expect a meaningful commercial or execution update, while skeptics emphasize the lack of new binding contracts, ongoing losses, and dilution risk.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

A speculative meme-token rally and claims of outperformance versus the broader crypto market have driven attention, with traders promoting 4CHANs 4chan-linked identity, Ethereum base, large token supply and purportedly locked or burned tokens. The community is strongly bullish and focused on holding for further momentum, while skeptics warn that the move could be a pump-and-dump and question the tokens utility and supply structure.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A bearish short report questioning the statistical power and valuation of SELLASs REGAL Phase 3 trial triggered the selloff and intensified attention ahead of the 80th-event and topline readout. Traders are sharply divided, with bulls arguing that prolonged patient survival and prior independent monitoring support GPS, while bears cite trial-design, control-arm, and disclosure concerns; separate debate over Stocktwits leadership has amplified the discussion.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

Renewed trading activity and speculation around Flexas payments roadmap are driving attention, particularly discussion of European/SEPA expansion, new leadership, and potential benefits from the U.S. CLARITY Act. Bulls view these as signs of future AMP utility and accumulation, while skeptics cite the tokens prolonged decline, sell walls, and repeated pump-and-dump behavior.

GE Vernova, Inc. engages in the electric power industry. It operates through the following segments: Power, Wind, and Electrification. The Power segment offers design, manufacture, and servicing gas, nuclear, hydro, and steam technologies, providing a critical foundation of dispatchable, flexible, stable, and reliable power. The Wind segment manages wind generation technologies, including onshore and offshore wind turbines and blades. The Electrification segment refers to the grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, storage, and orchestration of electricity from point of generation to point of consumption. The company was founded November 9, 2021 and is headquartered in Cambridge, MA.

GE Vernova Inc.

GE Vernovas latest quarterly results are driving attention: an earnings miss and wind-segment losses triggered a sharp selloff despite stronger orders, record backlog, and raised full-year revenue and free-cash-flow guidance. Traders are split between viewing the decline as a valuation/profit-taking warning and treating it as an overreaction to a temporary execution issue, while the longer-term AI data-center power and grid-infrastructure thesis remains widely debated.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Speculation around LUNC supply reductionthrough ongoing burns, Market Module 2.0, Binance fee burns, and possible court-related token destructionis driving attention, with traders linking these developments to a potential USTC repeg and Terra ecosystem revival. Bulls are accumulating on the comeback narrative, while bears argue that the massive supply, low liquidity, and repeated pump-and-dump patterns limit the impact of unconfirmed catalysts.

Pump.fun

A rebound in Pump.fun is drawing attention as traders point to protocol revenue, token buybacks and burns, and renewed activity across the Solana memecoin ecosystem as potential supports for the move. Sentiment is largely bullish around a technical recovery and further upside, though some traders cite unlocks, whale selling, weak participation, and the projects memecoin risks as reasons for caution.

Ethena

A proposed Ethena fee-switch and ENA buyback framework is driving attention, with traders also speculating that the upcoming Ethena X launch could accelerate USDe growth toward the buyback threshold. Sentiment is broadly bullish on the potential recurring demand, while others note that buybacks would not begin until USDe supply reaches the required level and that the launch remains uncertain.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck and Modernas personalized mRNA cancer vaccine, used with Keytruda, met recurrence-free and distant-metastasis-free survival endpoints in a Phase 3 melanoma trial, driving enthusiasm that the result validates Mercks oncology pipeline and could help extend the Keytruda franchise ahead of patent expiry. Traders remain divided, with skeptics citing limited topline detail, pending overall-survival and regulatory results, and valuation concerns.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Hawkish Federal Reserve messaging around the Jackson Hole speech lifted rate-hike expectations and Treasury yields, putting pressure on small caps and driving IWMs underperformance. Traders are debating whether the move signals further downsideciting heavy near-term put flow and technical resistanceor a temporary pullback that could rebound if rate fears ease.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates

Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of -50.00% and +10.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics (CYTK) Reports Q2 Loss, Beats Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of +7.98% and +40.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for May 27th

GYRE, FSUN and AKZOY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2026.

Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates

Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of +16.67% and -33.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Gyre Therapeutics (NASDAQ:GYRE) Trading Up 2% - Should You Buy?

Gyre Therapeutics (NASDAQ:GYRE) Trading 2% Higher - Here's What Happened...

Gyre Therapeutics (GYRE) to Release Earnings on Tuesday

Gyre Therapeutics (NASDAQ:GYRE) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 31. (View Earnings Report at...

Zacks Research Downgrades Gyre Therapeutics (NASDAQ:GYRE) to Strong Sell

Zacks Research lowered shares of Gyre Therapeutics from a "hold" rating to a "strong sell" rating in a report on Monday...

Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2% - Time to Sell?

Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2% - Should You Sell...

Gyre Therapeutics (NASDAQ:GYRE) Announces Earnings Results

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) posted its earnings results on Thursday. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). The...

Gyre Therapeutics (NASDAQ:GYRE) Downgraded by Wall Street Zen to Hold

Wall Street Zen cut Gyre Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday...

• Reported GAAP EPS of -$0.12
• Reported revenue of $29.11M up 8.72% YoY
• Gyre Therapeutics, Inc. affirmed its full year 2026 revenue guidance of $100.5 million to $111.0 million, reflecting the company's outlook for its commercial-stage biopharmaceutical product portfolio and development initiatives.

Gyre Therapeutics, Inc. experienced a wider net loss, a year-over-year decrease in quarterly revenues, and an 11% reduction in total cash position compared to the end of the prior year.

Gyre Therapeutics, Inc. expanded its pipeline through the strategic acquisition of Cullgen and achieved regulatory progress with F351 while driving higher sales volumes for its primary product, ETUARY.

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The firm operates two distinct segments: Gyre Pharmaceuticals and Gyre. The Gyre Pharmaceuticals segment extends three major commercial drug products including ETUARY, Etorel, and Contiva as well as several product candidates in preclinical and clinical development. The Gyre segment consists of the development and commercialization of Hydronidone for the treatment of metabolic dysfunction-associated steatohepatitis associated liver fibrosis. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

Gyre Therapeutics Inc

Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead

Equity

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a positive week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$6.59
Prev Close	$6.68
Open	$6.70
Dividend Yield	0.00%
50-Day Moving Average	$6.45
Beta	1.50
Avg. Volume	65,481.98
PE Ratio	-33.62

52-Week High	$9.42
52-Week Low	$5.44
Market Capitalization	$698.76M
EPS (Annual)	$0.0225
Price to Book	6.47
Revenue Per Employee	$186,540.80

Feed

News

Sentiment

Earnings

Fundamentals

Info